Verismo Therapeutics develops a novel KIR-CAR T cell platform designed to improve persistence and efficacy against aggressive solid tumors. Its lead asset, SynKIR-110, is a first-in-human KIR-CAR T cell therapy currently in a Phase 1 clinical trial. The company is also advancing SynKIR-310 in preclinical development for blood cancers. Verismo is positioned as a pioneer of dual-chain KIR-CAR technology and focuses on applications for advanced solid tumors, an area of high unmet need. The company plans to use new funding to continue the SynKIR-110 clinical trial and to support SynKIR-310 preclinical work. Verismo launched in 2020 and is based in Philadelphia, PA. Verismo Therapeutics, based in Philadelphia, is a clinical-stage company developing a KIR-CAR platform — a modified NK-like receptor engineered to improve persistence and efficacy against aggressive solid tumors. Its lead program, SynKIR-110™, is a first-in-class KIR-CAR T cell candidate for solid tumors, and the company is also developing SynKIR-310 for blood cancers. Led by CEO Dr. Bryan Kim, Verismo is on track to bring its first asset into first-in-human clinical trials in 2023. The company raised $7M in a pre-Series A financing to support continued advancement of the SynKIR-110 clinical trial and preclinical development of SynKIR-310. The financing was led by BRV Capital Management with participation from Ignite Innovation. The capital is intended to advance clinical and preclinical programs of the KIR-CAR platform in areas of high unmet medical need.

Total raised

$24M

Funding rounds

2

Latest round

Series A

Latest activity

Jul 2023